Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating XC221 for safety, tolerability, and efficacy in uncomplicated influenza and other acute viral upper respiratory infections has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Respiratory Infection
• Viral Upper Respiratory Infections

Drugs mentioned

• XC221

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Influenza, Viral Respiratory Infection | Phase 2 | Status: COMPLETED